Aservo EquiHaler wins Pharmapack Award 2021 Aservo EquiHaler wins Pharmapack Award 2021 Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Clinical trials deliver medical breakthroughs – but how do they happen? Clinical trials deliver medical breakthroughs – but how do they happen? Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Innovation from within Innovation from within Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Eugene Zalmover Eugene Zalmover Learn how Eugene’s work paved the way for digital innovation in Patient Safety.
Rafael Sani Simoes Rafael Sani Simoes Learn how Rafael’s role in Patient Safety enables him to make a difference.
Shimoli Shah Shimoli Shah Watch how Shimoli transitioned from practising clinician to Patient Safety Physician.
Samina Ajaz Hussain Samina Ajaz Hussain Discover how Samina never looked back on her career move to Patient Safety.
New positive data in Phase III type 2 diabetes trial New positive data in Phase III type 2 diabetes trial DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
A global production network against supply shortages A global production network against supply shortages The production of medicines is a complex process. We use our global production network to respond to increasing demand.
Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Global Computational Biology & Digital Sciences Global Computational Biology & Digital Sciences Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.
Translational Medicine & Clinical Pharmacology Translational Medicine & Clinical Pharmacology We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
Waste Waste Resource conservation at Boehringer Ingelheim is managed as part of an ongoing process of prevention and reduction of material usage and waste.
Digital innovation: „We change the way labs work“ Digital innovation: „We change the way labs work“ QUDA – an in-house software – changes the way labs work. It increases our quality assurance and our drug saftey.
Green Chemistry Green Chemistry Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
opening-solids-launch-fabrik opening-solids-launch-fabrik Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Biopharmaceuticals: large molecules, enormous potential Biopharmaceuticals: large molecules, enormous potential Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
More Health Overview More Health Overview Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.